Zobrazeno 1 - 10
of 216
pro vyhledávání: '"John H, Rex"'
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-10 (2019)
Non-traditional antibacterial agents are challenging to develop. In this Perspective, the authors argue that the distinction between traditional and non-traditional agents has only limited relevance for regulatory purposes, although products with non
Externí odkaz:
https://doaj.org/article/3146f09e95be41bd9cb39854de101287
Autor:
Kevin Outterson, John H. Rex
Publikováno v:
Applied Health Economics and Health Policy. 21:361-364
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00ef42bbf452cb9a3e1dd4d9303a76f2
https://doi.org/10.1007/s40258-023-00793-w
https://doi.org/10.1007/s40258-023-00793-w
Autor:
Yuliya Yasinskaya, Shukal Bala, Ursula Waack, Cheryl Dixon, Karen Higgins, Jason N Moore, Caroline J Jjingo, Elizabeth O'Shaughnessy, Philip Colangelo, Radu Botgros, Sumathi Nambiar, David Angulo, Aaron Dane, Tom Chiller, Michael R Hodges, Taylor Sandison, William Hope, Thomas J Walsh, Peter Pappas, Aspasia Katragkou, Laura Kovanda, John H Rex, Kieren A Marr, Luis Ostrosky-Zeichner, Shohko Sekine, Monika Deshpande, Sunita J Shukla, John Farley
Publikováno v:
Clinical Infectious Diseases.
Pressing challenges in the treatment of invasive fungal infections (IFIs) include emerging and rare pathogens, resistant/refractory infections, and antifungal armamentarium limited by toxicity, drug-drug interactions, and lack of oral formulations. D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13aeec0d6978925d410973556a32de81
https://doi.org/10.1093/cid/ciad195
https://doi.org/10.1093/cid/ciad195
Autor:
Karen Cornelissen, James G Wright, Andrew Cristinacce, Hal Galbraith, Roger Bruggemann, Johan A Maertens, George R Thompson, Sharon C Chen, John H Rex
Publikováno v:
Open Forum Infectious Diseases. 9
Background OLO is a novel antifungal active vs. Aspergillus (including azole-resistant strains), resistant moulds (e.g., Lomentospora prolificans), and dimorphic moulds. In preclinical PKPD studies, a plasma level ≥ 0.2 µg/mL was required for effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::675131ac5be4c6be90fe34a1555794c8
https://doi.org/10.1093/ofid/ofac492.647
https://doi.org/10.1093/ofid/ofac492.647
Autor:
Karen Cornelissen, Paul A Newell, John H Rex, Hal Galbraith, Samuel Israel, James Bush, M B ChB
Publikováno v:
Open Forum Infectious Diseases. 9
Background OLO is a novel antifungal active vs. Aspergillus (including azole-resistant strains), resistant moulds (e.g., Lomentospora prolificans), and dimorphic moulds. Information on absolute bioavailability and effect of food upon the pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d256235685cbf949a7157babd8333633
https://doi.org/10.1093/ofid/ofac492.646
https://doi.org/10.1093/ofid/ofac492.646
Autor:
Johan A Maertens, Paul E Verweij, Evan F Lanuza, Emma L Harvey, Aaron Dane, Daniela Zinzi, John H Rex, Sharon C Chen
Publikováno v:
Open Forum Infectious Diseases. 9
Background Olorofim is a novel antifungal agent active against Aspergillus spp (including azole-resistant strains), rare, resistant moulds (e.g., Lomentospora prolificans) and dimorphic moulds. Serial images of Lomentospora prolificans infection foll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::537f1e62e057fc0eebecc8fb28470a8c
https://doi.org/10.1093/ofid/ofac492.063
https://doi.org/10.1093/ofid/ofac492.063
Autor:
Johan A Maertens, George R Thompson, Andrej Spec, Sarah P Hammond, Bart Rijnders, P Lewis White, Oliver A Cornely, Lesley Fitton, Aaron Dane, John H Rex, Sharon C Chen
Publikováno v:
Open Forum Infectious Diseases. 9
Background Olorofim, the first orotomide antifungal, selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in fungal pyrimidine biosynthesis. Olorofim is active against Aspergillus (including azole-resistant and cryptic speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d450d5b501106ef3aad5be42c9d20873
https://doi.org/10.1093/ofid/ofac492.039
https://doi.org/10.1093/ofid/ofac492.039
Publikováno v:
Clin Infect Dis
Background Inaccessibility of medicines in low- and middle-income countries is a frequent challenge. Yet it is typically assumed that high-income countries have complete access to the full arsenal of medicines. This study tests this assumption for ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78678a569b2d179501e81f7516b85e7a
https://doi.org/10.1093/cid/ciab612
https://doi.org/10.1093/cid/ciab612
Autor:
William W. Hope, Laura McEntee, Joanne Livermore, Sarah Whalley, Adam Johnson, Nicola Farrington, Ruwanthi Kolamunnage-Dona, Julie Schwartz, Anthony Kennedy, Derek Law, Michael Birch, John H. Rex
Publikováno v:
mBio, Vol 8, Iss 4 (2017)
ABSTRACT F901318 is an antifungal agent with a novel mechanism of action and potent activity against Aspergillus spp. An understanding of the pharmacodynamics (PD) of F901318 is required for selection of effective regimens for study in phase II and I
Externí odkaz:
https://doaj.org/article/ee5b4c0c99644111aad9e0e94bbbb141
Autor:
Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, Laila Al-Sulaiman, John H. Rex, Prabhavathi Fernandes, Cesar A. Arias, Mical Paul, Guy E. Thwaites, Lloyd Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman Kozlov, Stephan Harbarth, Peter Beyer
Publikováno v:
Antimicrob Agents Chemother
There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76943be92776f3f4b8f59eb45535c2de
https://doi.org/10.1128/aac.01991-21
https://doi.org/10.1128/aac.01991-21
